Currently out of the existing stock ratings of Brian Cheng, 59 are a BUY (73.75%), 18 are a HOLD (22.5%), 3 are a SELL (3.75%).

Brian Cheng

Work Performance Price Targets & Ratings Chart

Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 43.75% that have a potential upside of 16.43% achieved within 67 days.

Brian Cheng’s has documented 155 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 07-Nov-2025.

Wall Street Analyst Brian Cheng

Analyst best performing recommendations are on CRGX (CARGO THERAPEUTICS, COMMON STOCK).
The best stock recommendation documented was for PTGX (PROTAGONIST THERAPEUTICS) at 3/4/2025. The price target of $57 was fulfilled within 7 days with a profit of $18.34 (47.44%) receiving and performance score of 67.77.

Average potential price target upside

of $15.72 (15.48%) on BPMC (BLUEPRINT MEDICINES CORP).
of $12.41 (54.79%) on SRRA (SIERRA ONCOLOGY).
of $10.8 (37.48%) on PTGX (PROTAGONIST THERAPEUTICS).

ARCT Arcturus Therapeutics Holdings PSTX Poseida Therapeutics ADCT ADC Therapeutics SA IMNM Immunome SRRA Sierra Oncology GOSS Gossamer Bio APLS Apellis Pharmaceuticals NTLA Intellia Therapeutics ROIV Roivant Sciences Ltd XNCR Xencor ACET Adicet Bio BCAB Bioatla ALLO Allogene Therapeutics MRSN Mersana Therapeutics PTGX Protagonist Therapeutics ZYME Zymeworks Common Stock BPMC Blueprint Medicines Corp EDIT Editas Medicine IMVT Immunovant CRGX CARGO Therapeutics, Common Stock KYTX Kyverna Therapeutics, Common Stock ITOS Iteos Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Yigal Nochomovitz (CITI)